Author

P. E. Barran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:protein folding & dynamics· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:E. coli· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Inga· 1 shared A. Karlen· 1 shared A. L. Okorokov· 1 shared A. P. Snijders· 1 shared A. Theisen· 1 shared A. Vema· 1 shared C. Spinnler· 1 shared D. Anastasiou· 1 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Inga

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Efficient overexpression and purification of SARS-CoV-2 Nucleocapsid proteins in Escherichia coli

E. L. Brudenell, M. B. Pohare, D. Zafred, J. Phipps, H. R. Hornsby, J. Darby, J. Dai, E. Liggett, K. Cain, P. E. Barran, T. I. de Silva, J. R. Sayers

The paper describes the scalable production and purification of SARS-CoV-2 nucleocapsid proteins in E. coli and evaluates their use in ELISA assays.

bioRxiv · Jan 8, 2024 · PreprintBiochemistry

Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy

J. Zawacka-Pankau, V. V. Grinkevich, M. Burmakin, A. Vema, K. Fawkner, N. Issaeva, V. Andreotti, E. R. Dickinson, E. Hedstrom, C. Spinnler, A. Inga, L.-G. Larsson, A. Karlen, O. Tarasova, V. Poroikov, , G. Selivanova

This study identifies a novel allosteric mechanism by which small molecules activate p53 by blocking MDM2/MDMX binding, offering a new approach for anticancer therapy.

bioRxiv · Dec 7, 2018 · PreprintCancer Biology

Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation

J. A. Macpherson, A. Theisen, L. Masino, L. Fets, P. C. Driscoll, V. Encheva, A. P. Snijders, S. R. Martin, J. Kleinjung, P. E. Barran, F. Fraternali, D. Anastasiou

The paper investigates how PKM2 activity is regulated by simultaneous binding of activating and inhibiting ligands, revealing a mechanism for integrating allosteric inputs.

bioRxiv · Jul 26, 2018Biochemistry